keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAPTA-AM is a calcium chelator that is cell-permeable and selective, blocking hERG, hKv1.3, and hKv1.5 channels (IC50=1.3/1.45/1.23 μM). BAPTA-AM has a 105-fold higher affinity for Ca2+ than for Mg2+, and can be used for the role of calcium in cell signaling.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 7,000 | |||
10 mg | 在庫あり | ¥ 12,000 | |||
25 mg | 在庫あり | お問い合わせ | |||
50 mg | 在庫あり | お問い合わせ | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 10,000 |
説明 | BAPTA-AM is a calcium chelator that is cell-permeable and selective, blocking hERG, hKv1.3, and hKv1.5 channels (IC50=1.3/1.45/1.23 μM). BAPTA-AM has a 105-fold higher affinity for Ca2+ than for Mg2+, and can be used for the role of calcium in cell signaling. |
ターゲット&IC50 | Kv1.3 (human, HEK293 cells):1.45 μM (IC50), Kv1.5 (human, HEK293 cells):1.23 μM (IC50), ERG channel (human, HEK293 cells):1.3 μM (IC50) |
In vitro |
METHODS: Chondrocytes were treated with BAPTA-AM (10 μM) and FAC (100 μM) for 24 h. Intracellular ROS levels were measured using the Reactive Oxygen Species Assay kit. RESULTS: FAC promoted ROS production and this effect was inhibited by the calcium chelator BAPTA-AM. [1] METHODS: Rat fibroblast RAT2 and Xenopus cells were treated with BAPTA-AM (50 μM) for 1 h, and microtubule depolymerization was detected by Immunostaining. RESULTS: BAPTA AM treatment for 30 min resulted in almost complete disassembly in most cells, and microtubules were uniformly depolymerized in cells within 60 min. [2] |
In vivo |
METHODS: To investigate the effect on ethanol-induced locomotor activity, BAPTA-AM (0-10 mg/kg, Cremophor EL 1.25% (v/v) in distilled water) was injected intraperitoneally into Swiss (RjOrl) mice, followed by ethanol (0-4 g/kg) 30 min later. RESULTS: Pretreatment with BAPTA-AM blocked the locomotor stimulus produced by ethanol without altering basal locomotion. On the contrary, BAPTA-AM reversed the ethanol-induced hypnosis. [3] METHODS: To investigate the effect on LPS-induced blood-brain barrier leakage, BAPTA-AM (12 mg/kg, 0.01% pluronic acid in sterile saline) was injected intravenously into FVB mice, followed 30 min later by intraperitoneal injection of LPS (25 mg/kg). RESULTS: BAPTA-AM reduced LPS-induced blood-brain barrier leakage. [4] |
別名 | BAPTA/AM |
分子量 | 764.68 |
分子式 | C34H40N2O18 |
CAS No. | 126150-97-8 |
keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (65.39 mM), Sonication is recommended.
5% DMSO+95% Saline: 7.25 mg/mL (9.48 mM, suspension)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BAPTA-AM 126150-97-8 Membrane transporter/Ion channel Potassium Channel inhibit BAPTA/AM Inhibitor KcsA BAPTA AM BAPTAAM inhibitor